Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
- S. Grisariu, B. Avni, T. Siegal
- MedicineBlood
- 17 June 2010
An aggressive multimodality therapy can prevent neurologic deterioration and is associated with a prolonged survival in a subset of patients.
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
- M. Weller, M. J. van den Bent, W. Wick
- MedicineNature Reviews Clinical Oncology
- 8 December 2020
These evidence-based guidelines incorporate major changes in diagnostic algorithms based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System as well as on evidence from recent large clinical trials.
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
- P. Wen, M. Weller, M. J. van den Bent
- MedicineNeuro-Oncology
- 24 April 2020
Novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Comparing explorative saccade and flicker training in hemianopia
- T. Roth, A. Sokolov, A. Messias, P. Roth, M. Weller, S. Trauzettel-Klosinski
- PsychologyNeurology
- 27 January 2009
The findings show substantial benefits of compensatory exploration training, including subjective improvements in mastering daily-life activities, in a randomized controlled trial.
EANO guidelines for the diagnosis and treatment of ependymal tumors.
- R. Rudà , G. Reifenberger, E. Moyal
- MedicineNeuro-Oncology
- 27 March 2018
Nine subgroups of ependymal tumors across different anatomical compartments have been identified with distinct genetic and epigenetic alterations, and with distinct outcomes, which may lead to more precise diagnostic and prognostic assessments, molecular subgroup-adapted therapies, and eventually new recommendations pending validation in prospective studies.
Molecular targeted therapy of glioblastoma.
- É. Le Rhun, M. Preusser, M. Weller
- Biology, MedicineCancer Treatment Reviews
- 11 September 2019
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- D. Reardon, A. Brandes, M. Weller
- MedicineJAMA Oncology
- 21 May 2020
Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.
Surgery for primary CNS lymphoma? Challenging a paradigm.
This analysis of the largest PCNSL trial ever performed challenges the traditional view that the extent of resection has no prognostic impact on this disease and proposes to reconsider the statement that efforts at resection should be discouraged.
A specific miRNA signature in the peripheral blood of glioblastoma patients
- P. Roth, J. Wischhusen, A. Keller
- Biology, ChemistryJournal of Neurochemistry
- 1 August 2011
J. Neurochem. (2011) 118, 449–457.
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
- L. Weinmann, J. Wischhusen, M. Weller
- BiologyCell Death and Differentiation
- 1 April 2008
It is revealed that P53R3 induces p53-dependent antiproliferative effects with much higher specificity and over a wider range of concentrations than the previously described p53 rescue drug p53 reactivation and induction of massive apoptosis (PRIMA-1).
...
...